4.3 Article

Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research

Journal

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
Volume 10, Issue 3, Pages 340-348

Publisher

BENTHAM SCIENCE PUBL
DOI: 10.2174/187152711794653742

Keywords

Autoimmune disease; glial activation; neuroinflammation; neurodegeneration; prolyl oligopeptidase

Funding

  1. European Commission [HEALTH-F2-2008-223077]
  2. Marie Curie Programme [PIEF-GA-2009-254127]

Ask authors/readers for more resources

Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available